受损股民可至新浪股民维权平台登记该公司维权：http://wq.finance.sina.com.cn/ 关注@新浪证券、微信关注新浪券商基金、百度搜索新浪股民维权、访问新浪财经客户端、 新浪财经首页都能找到我们！ 2026年2月13日，上海久诚律师事务所股票索赔许峰代理的易事特（维权）（300376）虚假陈述引发的 投资者索赔案再向广州市中级人民法院提交一次立案。（许峰律师专栏） 许峰律师提示，易事特投资者索赔案已有胜诉判决。2月上旬，许峰律师代理的部分投资者收到赔偿 款，已经获赔到位。律师团队同步还在推进后续案件的立案工作，还在继续接受其他投资者的索赔委 托。 2024年12月31日晚，易事特公告收到证监会《行政处罚决定书》，经查明，当事人存在以下违法事实： 一、易事特通过开展虚假贸易业务虚增营业收入、营业成本、利润总额。 二、易事特通过开展具有融资性质的代采业务和代理业务虚增营业收入、营业成本。 三、易事特通过开展具有融资性质的数据中心集成业务虚增营业收入、营业成本。 综上，易事特通过上述不具有商业实质的虚假贸易业务、融资性代采业务、代理业务和数据中心集成业 务虚增营业收入、营业成本、利润总额，导致易事 ...

Core Viewpoint - The news highlights ongoing legal actions regarding investor claims against Yingfeituo and Ningke Biological, with recent court rulings favoring investors in both cases, indicating potential for further claims and compensation opportunities for affected shareholders [1][2][4]. Group 1: Yingfeituo (002528) - The Shenzhen Intermediate People's Court has accepted a case for investor claims against Yingfeituo, with previous rulings resulting in a win for investors [1][4]. - Investors who purchased Yingfeituo shares between April 30, 2020, and April 30, 2024, and sold or held shares after April 30, 2024, are eligible to initiate claims [2][5]. - The company received a notice from the China Securities Regulatory Commission (CSRC) on January 24, 2025, regarding an investigation into information disclosure violations [4]. Group 2: Ningke Biological (600165) - Ningke Biological has faced legal actions due to false reporting in its 2022 annual report, which overstated revenue by 76.59 million and profit by 77.22 million, representing 11.25% and 46.59% of total revenue and profit, respectively [2][5]. - The company failed to timely disclose significant events, including major debts, frozen bank accounts, and a halt in key subsidiary operations [5][6]. - Investors who bought Ningke Biological shares between November 22, 2022, and April 6, 2023, or between April 28, 2024, and October 31, 2024, are also eligible to file claims [3][6].

Core Viewpoint - 聚石化学 has been found guilty of engaging in fraudulent activities to inflate revenue, costs, and profits, leading to potential legal actions from investors [1][2]. Group 1: 聚石化学 - 聚石化学 and its subsidiaries inflated revenue by conducting fictitious trade activities, resulting in a reported inflated revenue of 86,550,865.69 yuan and inflated costs of 88,238,071.82 yuan, leading to a profit reduction of 1,687,206.13 yuan [1]. - The company also engaged in transactions with third-party companies that lacked commercial substance, inflating both revenue and costs by 52,236,440.86 yuan, without affecting profits [1]. - In total, for the first half of 2023, 聚石化学 inflated its operating revenue by 156,807,377.35 yuan and operating costs by 158,470,264.89 yuan, which represented 8.32% and 8.51% of total revenue and costs, respectively [2]. Group 2: 中泰化学 - 中泰化学 has also faced legal scrutiny for inflating its revenue by 4,248,474,643.06 yuan in its 2022 annual report, which accounted for 7.60% of the reported total revenue [2][3]. - The company failed to disclose significant related-party transactions involving non-operating fund occupations in its annual reports for 2021 and 2022, leading to major omissions [3]. - Investors who purchased 中泰化学 stock between April 10, 2021, and March 21, 2024, may also initiate claims due to these violations [3].

关注@新浪证券、微信关注新浪券商基金、百度搜索新浪股民维权、访问新浪财经客户端、 新浪财经首页都能找到我们！ 2026年2月10日，上海久诚律师事务所股票索赔律师许代理的东方集团（600811）虚假陈述索赔案再向 哈尔滨市中级人民法院提交一次立案。（许峰律师专栏） 许峰律师代理的部分东方集团投资者索赔案已开庭，律师团队还在继续推进后续案件的立案工作，还在 继续接受后续投资者的索赔委托。 2025年3月16日晚，东方集团公告收到证监会《行政处罚事先告知书》，经查明，2020年至2023年，东 方集团出于维持农产品贸易市场占有率、满足融资需求以及业绩考核等目的，通过人为增加业务环节或 虚构业务链条等方式，长期开展农产品融资性贸易和空转循环贸易。上述虚假销售业务导致东方集团 2020年至2023年年度报告分别虚增营业收入3，896，546，638.75元、4，865，498，090.36元、6， 542，641，212.14元、824，804，130.07元，占各期对外披露营业收入（更正前，下同）的25.20%、 32.05%、50.44%、13.56%，分别虚增营业成本3，875，480，343.50元、4，84 ...

Core Viewpoint - The news highlights the administrative penalties imposed on 聚石化学 (Jushi Chemical) and 中泰化学 (Zhongtai Chemical) for engaging in fraudulent activities that inflated their financial statements, leading to potential investor claims for compensation [1][2][5]. Summary by Sections 聚石化学 (Jushi Chemical) - 聚石化学 was found to have inflated its revenue, costs, and profits through fictitious trade activities, including transactions with four companies that did not involve actual goods, resulting in a revenue inflation of approximately 86.55 million yuan and cost inflation of about 88.24 million yuan [1][2]. - The company also engaged in transactions that lacked commercial substance, inflating both revenue and costs by approximately 52.24 million yuan, without affecting profits [1][2]. - In total, for the first half of 2023, 聚石化学 inflated its operating revenue by approximately 156.81 million yuan and operating costs by about 158.47 million yuan, which represented 8.32% and 8.51% of total revenue and costs, respectively [2][5]. - Investors who purchased 聚石化学 stock between August 29, 2023, and November 22, 2025, may initiate claims for compensation due to these fraudulent activities [2][5]. 中泰化学 (Zhongtai Chemical) - 中泰化学 was found to have inflated its 2022 revenue and costs by approximately 4.25 billion yuan each, which accounted for 7.60% and 7.75% of the reported total revenue and costs in its annual report [6]. - The company failed to disclose significant related-party transactions involving non-operating fund occupations in its 2021 and 2022 annual reports, leading to major omissions [3][6]. - Investors who bought 中泰化学 stock between April 10, 2021, and March 21, 2024, are eligible to file claims for compensation due to the identified fraudulent activities [4][6].

受损股民可至新浪股民维权平台登记该公司维权：http://wq.finance.sina.com.cn/ 关注@新浪证券、微信关注新浪券商基金、百度搜索新浪股民维权、访问新浪财经客户端、 新浪财经首页都能找到我们！ 前期许峰律师代理的卓朗科技投资者索赔案在法院判决投资者胜诉后，投资者目前已经收到法院判定的 赔偿款项。许峰律师代理的卓朗科技投资者索赔已经获得胜诉以及获赔到位。律师团队同步还在继续推 进后续案件的立案工作，还在继续接受其他投资者的索赔委托。 2024年12月25日晚，卓朗科技公告收到证监会《行政处罚决定书》，经查，2019年至2023年，卓朗科技 子公司天津卓朗科技发展有限公司虚构服务器、软件和系统集成服务销售业务，虚增收入和利润。 上述虚假销售业务导致卓朗科技2019年至2023年年度报告分别虚增营业收入24，915.28万元、48， 912.89万元、33，861.50万元、65，612.78万元、8，225.45万元，占各期对外披露营业收入的21.05%、 45.19%、41.60%、72.46%、13.22%；分别虚增利润总额24，915.28万元、30，989.93万元、33，861.5 ...

Core Viewpoint - Zhuhai Huijin Technology Co., Ltd. (the "Company") is at risk of being delisted due to negative financial performance, as indicated in their announcements regarding potential termination of stock listing [2][3]. Financial Performance - The Company reported negative values for total profit, net profit, and net profit after deducting non-recurring gains and losses for the year 2024, with operating revenue below 100 million yuan [2]. - For the year 2025, the Company anticipates that the lowest of total profit, net profit, and net profit after deducting non-recurring gains and losses will also be negative, with projected operating revenue between 104.6 million and 116.6 million yuan [3]. Regulatory Compliance - The Company is required to disclose risk warnings regarding potential delisting within one month after the end of the fiscal year in which the delisting risk warning was implemented, and subsequently every ten trading days until the annual report is disclosed [3]. Legal and Compensation Aspects - Investors may seek compensation for losses incurred due to the Company's violations of information disclosure laws, as per the Securities Law and relevant judicial interpretations [6][9]. - The conditions for claiming compensation include purchasing the Company's stock between January 24, 2025, and March 28, 2025, and selling or holding the stock after March 29, 2025 [7]. Legal Team Background - The legal team led by lawyer Xie Baoping has successfully assisted numerous investors in recovering funds from over 100 stocks, with several cases recognized as exemplary by the courts [10].

Group 1 - Tian Sheng New Materials received a notice from the CSRC regarding a case of suspected information disclosure violations, potentially involving undisclosed related party transactions for the fiscal year 2023 [1] - The company has not yet received a final conclusion from the CSRC regarding the investigation, and the outcome will be determined by the CSRC's findings [1] - Investors who purchased Tian Sheng New Materials stock before February 6, 2026, and sold or held it afterward may be eligible for compensation [1] Group 2 - Century Huatong received an administrative penalty decision from the CSRC, revealing false records related to goodwill in annual reports from 2018 to 2022 [2] - The company was found to have fabricated software copyright transfer transactions or prematurely recognized revenue, leading to false records in annual reports for 2020-2021 [2] - Investors who bought Century Huatong stock between April 27, 2019, and July 25, 2023, and sold or held it afterward may also initiate claims for compensation [2]

Core Viewpoint - The articles discuss legal actions and potential claims against two companies, Cuihua Jewelry and Hainan Huatie, due to violations related to information disclosure and contract announcements [1][4]. Group 1: Cuihua Jewelry - Cuihua Jewelry received a notice from the China Securities Regulatory Commission (CSRC) regarding an investigation into alleged violations of information disclosure laws [1][4]. - Investors who purchased Cuihua Jewelry shares before February 10, 2026, and sold or held them after that date may prepare to initiate claims [1][4]. Group 2: Hainan Huatie - Hainan Huatie received an administrative penalty notice from the CSRC for incomplete disclosure of a significant contract, specifically a service agreement worth 3.69 billion yuan [2][4]. - The company failed to disclose critical terms of the contract that could significantly impact its execution, which constitutes a violation of disclosure regulations [2][4]. - Investors who bought Hainan Huatie shares between March 5, 2025, and October 1, 2025, and sold or held them after that date are also eligible to initiate claims [3][5].

Core Viewpoint - Tian Sheng New Materials and Century Huatong are facing legal actions due to violations of information disclosure regulations, leading to potential compensation claims for affected investors [1][2][4]. Group 1: Tian Sheng New Materials - On February 6, 2026, Tian Sheng New Materials received a notice from the CSRC regarding an investigation for suspected violations of information disclosure laws, particularly concerning undisclosed related party transactions for the year 2023 [1][3]. - The company has not yet received a final conclusion from the CSRC regarding the investigation, and the outcome will depend on the CSRC's findings [3]. - Investors who purchased Tian Sheng New Materials stock before February 6, 2026, and sold or continued to hold it afterward may be eligible to initiate compensation claims [4]. Group 2: Century Huatong - On November 6, 2024, Century Huatong announced it received an administrative penalty decision from the CSRC, revealing false records in its annual reports from 2018 to 2022 regarding goodwill and fictitious software copyright transfer transactions [2][4]. - Investors who bought Century Huatong stock between April 27, 2019, and July 25, 2023, and sold or continued to hold it afterward are also eligible to file compensation claims [5]. - The legal team is actively pursuing further claims and has already achieved compensation for some investors in previous cases [4][5].